Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes
Exscientia Plc - American Depositary Shares (EXAI)
Company Research
Source: Business Wire
Findings support deep learning ex vivo drug screening with patient tissue as a promising tool to identify effective, individual treatments in advanced blood cancer over conventional methodsCustom deep learning algorithms and single-cell analysis of 1 billion patient cells reveals further potential for improved patient outcomes VIENNA & OXFORD, England--(BUSINESS WIRE)--Exscientia (Nasdaq: EXAI), ETH Zurich, the Medical University of Vienna, and the Center for Molecular Medicine (CeMM) today announced a new publication in Blood Cancer Discovery, a journal of the American Association for Cancer Research, titled “Deep Morphology Learning Enhances Precision Medicine by Image-Based Ex Vivo Drug Testing” from the laboratory of Prof. Berend Snijder. This post-hoc analysis builds on the transformative work of the EXALT-1 trial, published in Cancer Discovery, by using deep learning algorithms to classify complex cell morphologies in patient cancer tissue samples into disease “morphotypes.”E
Show less
Read more
Impact Snapshot
Event Time:
EXAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAI alerts
High impacting Exscientia Plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
EXAI
News
- The Galien Foundation Announces 2024 Prix Galien International Awards NomineesPR Newswire
- Exscientia plc (NASDAQ: EXAI) had its "equal weight" rating re-affirmed by analysts at Morgan Stanley. They now have a $7.00 price target on the stock.MarketBeat
- The Race Between Biotech And Techbio [Forbes]Forbes
- Investigation into Exscientia Underway: Johnson Fistel, LLP Digs into Alleged Securities Law Violations - What Shareholders Need to KnowGlobeNewswire
- Investors who lost money on Exscientia plc should contact Levi & Korsinsky about an ongoing investigation - EXAIAccesswire
EXAI
Earnings
- 3/21/24 - Beat
EXAI
Sec Filings
- 4/24/24 - Form 144
- 4/22/24 - Form 6-K
- 4/8/24 - Form 144
- EXAI's page on the SEC website